https://orcid.org/0000-0002-2049-5536
References
- Xu J, Murphy SL, Kockanek KD, et al. Mortality in the United States, 2018. NCHS Data Brief. 2020;2020:1–8.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
- National Cancer Institute. Cancer Prevalence and Cost of Care Projections [Internet]. Cancer Prevalence and Cost of Care Projections; [cited 2021 Mar 24]. Available from: https://costprojections.cancer.gov/.
- Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the surveillance, epidemiology, and end results (SEER) program. Oncologist. 2003;8(6):541–552.
- Blumen H, Fitch K, Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23–32.
- Trogdon JG, Ekwueme DU, Poehler D, et al. Medical costs of treating breast cancer among younger medicaid beneficiaries by stage at diagnosis. Breast Cancer Res Treat. 2017;166(1):207–215.
- Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Canc Netw. 2018;16(4):402–410.
- Mariotto AB, Enewold L, Zhao J, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304–1312.
- Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674–686.
- Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US preventive services task force recommendation statement. JAMA. 2021;325(10):962–970.
- Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016;315(23):2564–2575.
- Department of Health. The Likely Impact of Earlier Diagnosis of Cancer on Costs and Benefits to the NHS [Internet]. 2011; [cited 2021 Mar 24]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/213788/dh_123576.pdf.
- National Cancer Institute - Surveillance, Epidemiology, and End Results Program. Overview of the SEER Program [Internet]. Overview of the SEER Program; [cited 2021. Mar 24]. Available from: https://seer.cancer.gov/about/overview.html.
- National Cancer Institute - Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts [Internet]; [cited 2021. Apr 28]. Available from: https://seer.cancer.gov/statfacts/.
- National Cancer Institute - Surveillance, Epidemiology, and End Results Program. SEER Combined/AJCC Cancer Staging [Internet]. SEER Combined/AJCC Cancer Staging; [cited 2021 Mar 26]. Available from: https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/.
- National Cancer Institute. Drugs Approved for Conditions Related to Cancer [Internet]. Drugs Approved for Conditions Related to Cancer; [cited 2020 Jan 21]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/related-conditions.
- Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50(272):1096–1121.
- Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors. J Clin Oncol Clin Cancer Inform. 2020; 4:1059–1071.